Biogen has notched up another victory in its attempts to keep generic versions of its Tecfidera (dimethyl fumarate) brand off the market in Europe. The European Patent Office’s opposition division has upheld the validity of the firm’s European patent EP2,653,873, which expires in February 2028.
The ‘873 patent claims treating relapsing remitting multiple sclerosis using dimethyl fumarate dosed at 480mg per day, which is the European